The pathophysiological process of Alzheimer’s disease (AD) is thought to begin many years
before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a …

In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …

Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from
a preclinical phase into a fully expressed clinical syndrome. We aimed to use longitudinal …

Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20 years)
and an average clinical duration of 8–10 years. The disease has an estimated prevalence …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a
purely biological definition of Alzheimer's disease that relies on biomarkers. Although the …

… In this study we sought to compare [ 11 C]PIB PET as a biomarker for Aβ burden in AD,
DLB, FTD, mild cognitive impairment (MCI), and normal elderly persons with previously …

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the
worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), recruited 1112 participants …

Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and
disease progression. Methods Clinical follow‐up was obtained 20 ± 3 months after [ 11 C]…

β-amyloid (Aβ) deposition is pathognomic for Alzheimer's disease (AD), but may occur in
normal elderly people without apparent cognitive effect. Episodic memory impairment is an …